초록 ▼

This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable

This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion barrier. In this invention, thrombin is no longer the variable which governs the tightness and the porosity of the fibrin material obtained, but still controls the clotting time. The mechanical behavior, high-water capacity, and releasable retention properties for therapeutic agents of this fibrin structure causes the fibrin material to be ideally suited for use as a drug delivery device, capable of delivering proteins, hormones, enzymes, antibiotics, antineoplastic agents and even cells for local and systemic treatment of human and non-human patients.

대표청구항 ▼

1. A fibrin hydrogel material comprising:a fibrin material, wherein the hydrogel material having has a water content of at least 90% by weight of the hydrogel material and whereby the hydrogel material retains from about 80% to about 90% of the water upon compression by a force from about 1 psi to a

1. A fibrin hydrogel material comprising:a fibrin material, wherein the hydrogel material having has a water content of at least 90% by weight of the hydrogel material and whereby the hydrogel material retains from about 80% to about 90% of the water upon compression by a force from about 1 psi to about 14 psi. 2. The fibrin hydrogel material of claim 1 wherein the fibrin hydrogel material has a pore size within the range of from about 0.1 μm to about 5.0 μm.3. A fibrin hydrogel material comprising: a fibrin material, wherein the hydrogel material has a water content of at least 90% by weight of the hydrogel material and whereby the hydrogel material retains from about 80% to about 50% of the water upon compression by a force from about 1 psi to about 14 psi wherein the fibrin hydrogel material is produced using an essentially calcium free thrombin solution.4. The fibrin hydrogel material of claim 1 having an optical clarity of less than about 1.0 AUFS when measured with a spectrophotometer at 800 nm.5. The fibrin hydrogel material of claim 1 substantial free of gamma-gamma cross-linking, as determined through gel electrophoresis.6. The fibrin hydrogel material of claim 1 having anti-adhesive properties.7. A method for producing a fibrin hydrogel material of claim 1, the method comprising the steps of:providing a fibrinogen reagent; providing a calcium chelating agent; providing a catalyst reagent essentially free of calcium; and mixing the fibrinogen, the chelating agent, and the catalyst to form the fibrin hydrogel material. 8. The method of claim 7 wherein the fibrinogen reagent comprises fibrinogen carried in a first diluent.9. The method of claim 8 wherein the first diluent is a phosphate buffered saline solution.10. The method of claim 9 wherein fibrinogen has a concentration from about 1.5 mg/ml to about 100 mg/ml.11. The method of claim 7 wherein the catalyst reagent comprises thrombin.12. The method of claim 11 wherein the catalyst reagent comprises thrombin carried in a second diluent.13. The method of claim 12 wherein the second diluent is a phosphate buffered saline solution.14. The method of claim 11 wherein thrombin has a concentration from about 1 IU/ml to about 1000 IU/ml.15. The method of claim 7 wherein the chelating agent is EGTA.16. The method of claim 7 wherein the chelating agent is EDTA.17. The method of claim 7 wherein the chelating agent is citrate.18. The method of claim 7 wherein the fibrin hydrogel material car be fabricated into articles selected from the group consisting of fins, tubes, and pellets.19. The method of claim 18 wherein the fibrin hydrogel material can be fabricated into articles using techniques selected from the group of extrusion, molding and thermal forming.20. The method of claim 18 wherein the fibrin hydrogel material can be sterilized at a temperature below 0° C. by gamma radiation, stored at a temperature below 0° C., and used upon demand.21. The method of claim 19 wherein the sterilization by gamma radiation is below 25° C., at a dosage of at least 25 kGy.22. A multiple layer fibrin material comprising:a fibrin glue layer; and a fibrin hydrogel layer, the fibrin hydrogel being capable of retaining from at least about 80% to about 90% of water by weight of the hydrogel when compressed by a force of 1-14 psi, and having relatively no cross-linking. 23. The multiple layer fibrin material of claim 22 wherein the fibrin glue layer has a pore size from about 2 μm to about 10 μm.24. The multiple layer fibrin material of claim 22 wherein the fibrin hydrogel layer has a pore size from about 0.1 μm to about 5 μm.25. The multiple layer fibrin material of claim 22 further including a fibrin layer, and being substantially cross-linked.26. The multiple layer fibrin material of claim 25 wherein the fibrin hydrogel layer has a pore size from about 0.1 μm to about 5 μm.27. The multiple layer fibrin material of claim 22 wherein the multiple layer fibrin material has anti-adhesive properties.28. A multiple layer fibrin material for treating a patient comprising:a fibrin film layer; and a fibrin hydrogel layer, the fibrin hydrogel having a water content of at least 90% by weight of the fibrin hydrogel and whereby the fibrin hydrogel retains from about 80% to about 90% of the water upon compression by a force from about 1 psi to about 14 psi. 29. The multiple layer fibrin material of claim 28 wherein the multiple layer fibrin material has anti-adhesive properties.30. The multiple layer fibrin material of claim 28 wherein the fibrin film layer has a pore size from about 2 μm to about 10 μm.31. The multiple layer fibrin material of claim 28 wherein the fibrin hydrogel layer has a pore size from about 0.1 μm to about 5 μm.32. The multiple layer fibrin material of claim 28 further including a therapeutic fibrin hydrogel layer.33. The multiple layer fibrin material of claim 32 wherein the therapeutic fibrin hydrogel layer has a pore size from about 0.1 μm to about 5 μm.34. The multiple layer fibrin material of claim 28 whereby the retained water comprises a releasably retained diluent.35. The multiple layer fibrin material of claim 34 whereby the releasably retained diluent is selected from the group consisting of antibiotics, fibrinolytic agents and biological response modifiers.36. The multiple layer fibrin material of claim 35 whereby the therapeutic agent comprises a pharmaceutical compound.37. The multiple layer fibrin material of claim 35 whereby the therapeutic agent comprises living cells.38. A multiple layer fibrin material for treating a patient comprising:a fibrin film layer; a therapeutic fibrin hydrogel layer, the fibrin hydrogel having a water content of at least 90% by weight of the fibrin hydrogel and whereby the fibrin hydrogel retains from about 80% to about 90% of the water upon compression by a force from about 1 psi to about 14 psi; and a fibrin glue layer attaching the fibrin film layer to the fibrin hydrogel layer. 39. The multiple layer fibrin material of claim 38 wherein the fibrin film layer has a pore size form about 2 μm to about 10 μm.40. The multiple layer fibrin material of claim 38 wherein the multiple layer fibrin material has anti-adhesive properties.41. The multiple layer fibrin material of claim 38 wherein the therapeutic fibrin hydrogel has a pore size from about 0.1 μm to about 5 μm.42. The multiple layer fibrin material of claim 38 whereby the retained water comprises a releasably retained diluent.43. The multiple layer fibrin material of claim 42 whereby the releasably retained diluent comprises a therapeutic agent.44. The multiple layer fibrin material of claim 43 whereby the therapeutic agent is selected from the group consisting of antibiotics, fibrinolytic agents and biological response modifiers.45. The multiple layer fibrin material of claim 43 whereby the therapeutic agent comprises living cells.